Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6554-6564

  Couvé, Sophie ^a,b,k   Ladroue, Charline ^a,b   Laine, Elodie ^c,d   Mahtouk, Karène ^a,b   Guégan, Justine ^e   Gad, Sophie ^a,b,k   Le Jeune, Hélène ^a,b   Le Gentil, Marion ^e   Nuel, Gregory ^f   Kim, William Y ^g   Lecomte, Bernard ^h   Pagès, Jean Christophe ⁱ   Collin, Christine ⁱ   Lasne, Françoise ^j   Benusiglio, Patrick R ^b,k   Bressac De Paillerets, Brigitte ^k,l   Feunteun, Jean ^m   Lazar, Vladimir ^e   Gimenez Roqueplo, Anne Paule ^k,n,o,p   Mazure, Nathalie M ^q   Dessen, Philippe ^e   Tchertanov, Luba ^c   Mole, David R ^r   Kaelin, William ^s   Ratcliffe, Peter ^r   Richard, Stéphane ^a,b,k,t   Gardie, Betty ^a,m   more..

^a PSL RESEARCH UNIVERSITY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Ecole Normale Superieure de Cachan   (France)

^d UMR 7238   (France)

^e Plate Forme de Génomique Gustave Roussy Cancer Campus ^*  (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h Médecine Générale   (Belgium)

ⁱ UNIVERSITÉ DE TOURS   (France)

^j Agence Française de Lutte contre le Dopage AFLD   (France)

^k Centre Expert National Cancers Rares INCa PREDIR Service d'Urologie Hôpitaux de Paris   (France)

^l Service de Génétique Gustave Roussy Cancer Campus   (France)

^m CNRS   (France)

ⁿ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^o PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^p UNIVERSITÉ PARIS DESCARTES   (France)

^q UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^r UNIVERSITY OF OXFORD   (United Kingdom)

^s HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^t UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARCINOGENESIS; CASE REPORT; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOXIA; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; ONCOGENE; PHENOTYPE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SPECIFICITY; TRANSCRIPTOMICS; VHL GENE; GENETICS; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MUTATION; PHEOCHROMOCYTOMA; PHYSIOLOGY;

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOGENESIS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR DYNAMICS SIMULATION; MUTATION; PHEOCHROMOCYTOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84918528332     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1161     Document Type: Article

References (53)

1. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011;476:163-9.
2. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
3. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHLElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999;284:455-61.
4. Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996;33:328-32.
5. Nordstrom-O'Brien M, Van Der Luijt RB, Van Rooijen E, Van Den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat 2010;31:521-37.
6. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 2007;27:5381-92.
7. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7.
8. Maranchie JK, Afonso A, Albert PS, Kalyandrug S, Phillips JL, Zhou S, et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat 2004;23:40-6.
9. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32:614-21.
10. Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res 2004;64:8595-603.
11. Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004;103:3924-32.
12. Bento C, Percy MJ, Gardie B, Maia TM, Van Wijk R, Perrotta S, et al. Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat 2014;35:15-26.
13. Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest 2007;117:3879-89.
14. Kapralova K, Lanikova L, Lorenzo F, Song J, Horvathova M, Divoky V, et al. RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood 2014;123:391-4.
15. Bond J, Gale DP, Connor T, Adams S, De Boer J, Gascoyne DM, et al. Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood 2011;117:3699-701.
16. Sarangi S, Lanikova L, Kapralova K, Acharya S, Swierczek S, Lipton JM, et al. The homozygous VHL missense mutation is associated with dramatically elevated erythropoietin levels, consequent polycythemia, and early onset severe pulmonary hypertension. Pediatr Blood Cancer 2014;61:2104-6.
17. Cario H, Schwarz K, Jorch N, Kyank U, Petrides PE, Schneider DT, et al. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 2005;90:19-24.
18. Liu E, Percy MJ, Amos CI, Guan Y, Shete S, Stockton DW, et al. The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood 2004;103:1937-40.
19. Woodward ER, Wall K, Forsyth J, Macdonald F, Maher ER. VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. Brain 2007;130:836-42.
20. Olschwang S, Richard S, Boisson C, Giraud S, Laurent-Puig P, Resche F, et al. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Hum Mutat 1998;12:424-30.
21. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-57.
22. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 2002;296:1886-9.
23. Kim M, Yan Y, Lee K, Sgagias M, Cowan KH. Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse. Biochem Biophys Res Commun 2004;320:945-50.
24. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, et al. Genome-wide association of hypoxia-inducible factor (HIF) - 1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009;284:16767-75.
25. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 2006;281:15215-26.
26. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in vonhippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009;69:4674-81.
27. Liu J, Nussinov R. The mechanism of ubiquitination in the cullin-RING E3 ligase machinery: conformational control of substrate orientation. PLoS Comput Biol 2009;5:e1000527.
28. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
29. Schodel J, Bardella C, Sciesielski LK, Brown JM, Pugh CW, Buckle V, et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat Genet 2012;44:420-5, S1-2.
30. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 2006;91:4593-8.
31. Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012;367:922-30.
32. Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 2012;72:112-21.
33. Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 2012;72:5273-84.
34. Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, et al. The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. Clin Cancer Res 2013;19:5740-8.
35. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001;10:1029-38.
36. Hacker KE, Lee CM, Rathmell WK. VHL type 2B mutations retain VBC complex form and function. PLoS ONE 2008;3:e3801.
37. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 2004;1654:105-22.
38. Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, et al. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med 2011;17:845-53.
39. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, et al. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet 1997;60:765-71.
40. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005;8:155-67.
41. Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H, et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 1995;95:551-6.
42. Gallou C, Chauveau D, Richard S, Joly D, Giraud S, Olschwang S, et al. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat 2004;24:215-24.
43. Bento MC, Chang KT, Guan Y, Liu E, Caldas G, Gatti RA, et al. Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. Haematologica 2005;90:128-9.
44. Capodimonti S, Teofili L, Martini M, Cenci T, Iachininoto MG, Nuzzolo ER, et al. Von hippel-lindau disease and erythrocytosis. J Clin Oncol 2012;30:e137-9.
45. Lorenzo FR, Yang C, Lanikova L, Butros L, Zhuang Z, Prchal JT. Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemia. Br J Haematol 2013;162:851-3.
46. Pastore Y, Jedlickova K, Guan Y, Liu E, Fahner J, Hasle H, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 2003;73:412-9.
47. Pastore YD, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K, et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003;101:1591-5.
48. Ritter MM, Frilling A, Crossey PA, Hoppner W, Maher ER, Mulligan L, et al. Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab 1996;81:1035-7.
49. Gardie B, Percy M, Hoogewijs D, Chowdhury R, Bento C, Arsenault P, et al. The role of PHD2 mutations in the pathogenesis of erythrocytosis. Hypoxia 2014;2:71-90.
50. Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008;359:2685-92.
51. Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med 2013;91:507-12.
52. Ladroue C, Hoogewijs D, Gad S, Carcenac R, Storti F, Barrois M, et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica 2012;97:9-14.
53. Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E. PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci US A 2008;105:4745-50.